Stock LTRN LANTERN PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
4.93 USD -10.36% Intraday chart for Lantern Pharma Inc. -13.81% +15.19%
Apr. 24 Transcript : Lantern Pharma Inc. - Special Call
Apr. 22 Lantern Gets Regulatory Approval in Japan, Taiwan for Non-Small Cell Lung Cancer Trial Expansion MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lantern Pharma Launches Webinar Wednesdays Featuring World-Class Physician Scientists and Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
AQ
Transcript : Lantern Pharma Inc. - Special Call
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
BU
Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
AQ
Lantern Gets Regulatory Approval in Japan, Taiwan for Non-Small Cell Lung Cancer Trial Expansion
MT
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
BU
Lantern Pharma Inc. Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smakers into Japan and Taiwan
CI
Lantern Pharma : Corporate Overview
PU
Transcript : Lantern Pharma Inc., Q4 2023 Earnings Call, Mar 18, 2024
Lantern Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
BU
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
BU
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, Lp-284
CI
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
BU
Lantern to Participate in H.C Wainwright and Co.'s 1st Annual Artificial Intelligence Based Drug Discovery and Development Virtual Conference
AQ
Lantern Pharma's A.I. Platform, RADR, Surpasses 60 Billion Data Points, Anticipates Reaching 100 Billion Data Points in 2024, paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
AQ
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
BU
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
BU
Lantern Pharma Inc. Announces Series of Important Milestones Related to the Development, Size, and Advancement of RADR
CI
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LTRN Stock
  4. News Lantern Pharma Inc.